Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glivec + hydroxyurea with postoperative radiotherapy in newly diagnosed glioblastoma
2006-001980-41Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib and Hydreasyn in glioblastoma (GBM) (2 arms), sponsored by Novartis. Primary endpoints: Maximum tolerated dose of imatinib and Dose-limiting toxicities. Started Nov 2006; status: completed.
02
Drugs
imatinibHydreasyn
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2006-001980-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001980-41.